Compound versions of some weight loss drugs to be restricted
Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...
Maine announces settlement to reduce insulin costs
There is good news for Mainers who rely on insulin according to our media partners WMTW. Maine Attorney General Aaron Frey ...
STAT12h
Eli Lilly’s Dave Ricks takes home $114 million as obesity drugs fuel company’s fortunes
Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.
Compound versions of weight loss drugs will no longer be available, FDA rules
The FDA says state-licensed compounding pharmacies must immediately stop making compound versions of GLP-1 drugs. Larger, national licensed facilities making compound versions of Zepbound have until ...
Is Eli Lilly and Company (LLY) the Best Low Risk Stock to Buy In 2025?
We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at ...
The Pharma Letter20h
Semaglutide and tirzepatide potential to transform type 1 diabetes treatment
A recent study published in Diabetes Technology & Therapeutics has demonstrated that the off-label use of semaglutide and ...
Morgan Stanley says REDEFINE-2 misses opportunity to differentiate in diabetes
Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety ...
Zacks Investment Research on MSN21h
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?
Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...